Welcome to our dedicated page for PMCBD news (Ticker: PMCBD), a resource for investors and traders seeking the latest updates and insights on PMCBD stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PMCBD's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PMCBD's position in the market.
PharmaCyte Biotech has received approval from Nasdaq to list its common stock under the symbol “PMCB.” The company plans to conduct an underwritten public offering of its common stock, which may include pre-funded warrants. H.C. Wainwright will manage the offering, which might also include a 30-day option for the underwriter to purchase additional shares. The proceeds will fund activities to address the FDA's clinical hold on its Investigational New Drug application for a Phase 2b trial in pancreatic cancer and for general working capital.
PharmaCyte Biotech (OTCQB: PMCBD) announced recognition from three independent publications discussing its pancreatic cancer treatments using the Cell-in-a-Box® technology. CEO Kenneth L. Waggoner confirmed the company remains above the price requirement for a potential Nasdaq uplist. Notable findings from clinical trials highlight median survival doubling with lower doses of ifosfamide. Recent publications validate PharmaCyte's approach, citing significant advancements in treating pancreatic cancer. The company aims to begin a Phase 2b clinical trial pending FDA approval.
PharmaCyte Biotech, Inc. (OTCQB: PMCBD, PMCB) announced that its original cytochrome P450 expressing cells from its Master Cell Bank have retained viability and enzymatic activity after three years in liquid nitrogen. This data is vital for the ongoing development of its CypCaps product, a treatment for cancer utilizing encapsulated cells to activate chemotherapy drugs like ifosfamide efficiently.
The study will continue for three more years to ensure the stability of these cells for future clinical trials.
